Phase 1 N=24 Safety Study of Capecitabine With Radiation in Elderly Rectal Cancer
Rectal Neoplasms
Primary: Number of Participants Experienced Dose Limited Toxicity — 0; 1; 1; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=18 Taste Assessment Study of SHP429 in Healthy Adult Subjects
Healthy
Primary: Number of Participants With Positive Responses to Palatability Assessment of The Taste of Mesalamine — 17; 16; 13 participants
Phase 1 N=52 Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants
Bioavailability
Primary: Cmax: Maximum Observed Plasma Concentration for Dexlansoprazole on Day 1. — 1046.8846; 1164.3654 ng/mL
Phase 1 N=24 Healthy Volunteer Study of the Pharmacokinetics of Oral Piperaquine With OZ439 + TPGS Formulation in the Fasted State
Malaria
Primary: OZ439 Cmax — 1540; 1360; 1610 ng/mL
Phase 1 N=5 Viral Kinetics in HCV Clearance in Subjects With Hemophilia
Chronic Hepatitis C · Hemophilia
Primary: Number of Participants With Sustained Virological Response at Week 12 (SVR12) — 2; 2 participants
Phase 1 N=30 Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers
Glaucoma · Ocular Hypertension
Primary: Cmax of Carteolol — 0.8558; 0.9984; 1.174; 1.627 ng/mL
Phase 1 N=16 Computer Vision System for the Blind Veteran
Blindness
Primary: Frequency of Device Failures Per Attempt to Complete a Navigation Course — 4.1; 2 number of device failures per attempt
Phase 1 N=328 Vitamin D for Chemoprevention
Gastrointestinal Cancers · Prostate Cancer · Hypertension
Primary: Levels of Plasma 25(OH)D at Baseline, 3 Months and 6 Months. — 15.1; 16.2; 13.9; 15.7 ng/mL
Phase 1 N=33 Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Phase II: Overall Response Rate — 21.8 Percentage of Participants
Phase 1 N=57 Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration
Age-Related Maculopathy · Age-Related Maculopathies · Eye Diseases
Primary: Incidence and Severity of Ocular Adverse Events (AEs) — 1; 3; 2; 1 participants
Phase 1 N=24 Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10
Healthy
Primary: the Cases of Adverse Events With Participant Injection of ESAT6-CFP10 — 3; 1; 0; 0 cases
Phase 1 N=70 A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase — 14; 6; 7; 6 participants
Phase 1 N=12 A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer
Breast Cancer
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0 Participants
Phase 1 N=6 ADSC Injections for Pain Management of Osteoarthritis in the Human Knee Joint
Osteoarthritis of the Knee
Primary: Safety as Measured by Adverse Events — 0 percentage of participants
Phase 1 N=30 Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women
Healthy
Primary: Mean Baseline GH Concentration — 0.23; 0.096 ug/L — p=<0.05